Literature DB >> 6365987

Acute disseminated histiocytosis-X: in situ immunophenotyping with monoclonal antibodies.

J D Bos, J H Sillevis Smitt, S R Krieg, P M Bakker, G D Vos, D J van Zaane.   

Abstract

The proliferating skin cells in a case of acute disseminated histiocytosis-X (Abt-Letterer-Siwe disease) confirmed by electron microscopy, were characterized by a panel of monoclonal antibodies using an immunoperoxidase technique. The "histiocytes" were found to stain with OKT-6 (anti-T6) and anti-HLA-DR antibodies. Unexpectedly, slight staining was also observed with Leu 3a (anti-T4) and OKM-1. A proliferative process of T4, T6, HLA-DR, OKM-1 positive Langerhans' cells has not yet been described and may be specific for histiocytosis-X.

Mesh:

Substances:

Year:  1984        PMID: 6365987     DOI: 10.1111/j.1600-0560.1984.tb00350.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  5 in total

1.  Immunohistochemical study of the abnormal cells in Langerhans cell histiocytosis (histiocytosis x).

Authors:  K Ornvold; E Ralfkiaer; H Carstensen
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

2.  Histiocytosis-X cells express C3b, C3d, and C3bi receptor (CR1, CR2, and CR3) antigens.

Authors:  T Bieber; D Hanau; E Heid; M D Kazatchkine
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

3.  Suppressor-cell dysfunction in children with histiocytosis-X.

Authors:  B T Shannon; W A Newton
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

4.  Immunohistochemical studies using monoclonal antibodies on lymph nodes from patients with mycosis fungoides and Sézary's syndrome.

Authors:  R Willemze; E Scheffer; C J Meijer
Journal:  Am J Pathol       Date:  1985-07       Impact factor: 4.307

5.  Langerhans Cell Histiocytosis Shows Distinct Cytoplasmic Expression of Major Histocompatibility Class II Antigens.

Authors:  Lucas Redd; Monika Schmelz; W Richard Burack; James R Cook; Antony W Day; Lisa Rimsza
Journal:  J Hematop       Date:  2016-03-10       Impact factor: 0.196

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.